Race executes global license agreement with City of Hope to access FTO IP

A summary of the material terms of the Agreement can be found on page 3 of the ASX Announcement here. A summary of the material terms of the Agreement can be found on page 3 of the ASX Announcementhere. CEO and Managing Director,Damian Clarke-Brucecommented: "In 2020, City of Hope published research highlighting bisantrene as a potent inhibitor of FTO. This exclusive worldwide agreement secures access for Race to important IP associated with that work and opens exciting...

A summary of the material terms of the Agreement can be found on page 3 of the ASX Announcement here.

CEO and Managing Director, Damian Clarke-Bruce commented: "In 2020, City of Hope published research highlighting bisantrene as a potent inhibitor of FTO. This exclusive worldwide agreement secures access for Race to important IP associated with that work and opens exciting opportunities for us to collaborate closely with Professor Jianjun Chen and his research group.

With the agreement in place, collaborative discussions regarding Race-sponsored research are now easier to facilitate. Moreover, this agreement secures a clear path for Race's FTO research agenda. We are excited about further validating this targeted application for bisantrene through preclinical and clinical studies and anticipate that FTO inhibition may offer a high-impact, personalised medicine solution for cancer patients."

 

View original content:https://www.prnewswire.co.uk/news-releases/race-executes-global-license-agreement-with-city-of-hope-to-access-fto-ip-301872703.html